🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10292971

Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs

Olema Pharmaceuticals, Inc. · Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10287340

Anti-HIV domain antibodies and method of making and using same

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10285986

Compounds and anti-tumor NQO1 substrates

The Board of Regents of the University of Texas System · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273307

Humanized anti-CD134 (OX40) antibodies and uses thereof

Biocerox Products B.V. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10265410

Adverse side-effects associated with administration of an anti-hyaluronan agent and method

HALOZYME, INC. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10259870

Anti-ANGPTL8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10261095

Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment

Julius-Maximilians-Universitat Wurzburg · Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238710

Peptide having anti-inflammatory, osteogenic and hair growth promoting activities, and use

CAREGEN CO., LTD. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10232042

Conjugates of an anti-TNF-alpha antibody

Nektar Therapeutics · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233244

Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10227362

Anti-pulmonary tuberculosis nitroimidazole derivative

Medshine Discovery Inc. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10214522

Anti-alphavbeta1 integrin inhibitors and methods of use

The Regents of the University of California · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206897

Creatine ester anti-inflammatory compounds and formulations

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10207993

Compounds as anti-tubercular agents

DRUG DISCOVERY RESEARCH CENTRE · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10202397

Anti-cancer compounds targeting Ral GTPases and methods of using the same

The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196458

Anti-immunoglobulin E antibodies and methods of using thereof

The Regents of the University of California · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196450

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10183011

Anti-depression compounds

The Board of Regents of the University of Texas System · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10182984

Targeted interferons demonstrate potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10179819

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10179817

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10172937

Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

Five Prime Therapeutics, Inc. · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10174098

Anti-human papillomavirus 16 E7 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted